ArticleMolecular and clinical oncology2022
Prognostic value of serum CEA and CA19-9 levels in pancreatic ductal adenocarcinoma.
Article in Molecular and clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 37 citations in OpenAlex.
- Preoperative Biomarker Panel With Fibrinogen, FVIII, and CA 19-9 as a Tool for Prognostic Evaluation in Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma.Cancer medicine · 2026Article
- Review
- Catching pancreatic cancer early: Are we there yet?Journal of the National Cancer Center · 2026Review
- <p>Unveiling sex differences in pancreatic ductal adenocarcinoma: Current evidence and future directions (Review)</p>.International journal of oncology · 2026Review
- Development of an artificial intelligence-based prediction platform for early recurrence of resectable pancreatic cancer after curative surgery-toward future use as an indication for neoadjuvant treatment: a retrospective multicenter cohort study.Annals of surgical treatment and research · 2026Article
- Synergistic Effect of Fecal Microbiota Transplantation, γδT Cell Immunotherapy, and Pembrolizumab in Refractory Advanced Pancreatic Cancer: A Case Report.Journal of gastrointestinal cancer · 2026Article
- Clinical diagnostic value of serum CEA and CA19-9 in patients with advanced pancreatic cancer: A prognostic cohort study.Frontiers in oncology · 2026Article
- CA19-9 as a Dynamic Biomarker for Continuous Monitoring of Therapeutic Efficacy in Pancreatic Adenocarcinoma.Cancers · 2025Review
- Article
- Study of serum tumor markers in the early diagnosis of pancreatic cancer.World journal of gastrointestinal oncology · 2025Article
- Cell-free DNA testing for the detection and prognosis prediction of pancreatic cancer.Nature communications · 2025Article
- Prognostic Impact of Phenotypic and Genetic Features of Pancreatic Malignancies.Life (Basel, Switzerland) · 2025Review
- Impact of portal/superior mesenteric vein abutment angle on prognosis in pancreatic cancer: a single-center retrospective cohort study.Annals of surgical treatment and research · 2025Article
- Serum-derived exosomal miR-7977 combined with miR-451a as a potential biomarker for pancreatic ductal adenocarcinoma.BMC cancer · 2025Article
- Impact of CT-relevant Skeletal Muscle Parameters on Post-chemotherapy Survival in Patients with Unresectable Pancreatic Ductal AdenocarcinomaCurrent medical imaging · 2025Article
- Clinical significance of risk factor analysis in pancreatic cancer by using supervised model of machine learning.Frontiers in medicine · 2025Article
- Construction of a combined prognostic model for pancreatic ductal adenocarcinoma based on deep learning and digital pathology images.BMC gastroenterology · 2024Article
- Review
- A Quest for Survival: A Review of the Early Biomarkers of Pancreatic Cancer and the Most Effective Approaches at Present.Biomolecules · 2024Review
- Significantly Elevated CA 19-9 after COVID-19 Vaccination and Literature Review of Non-Cancerous Cases with CA 19-9 > 1000 U/mL.Journal of clinical medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study investigated the associations of serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) levels with clinicopathological variables and survival outcomes in Libyan patients with pancreatic ductal adenocarcinoma (PDAC). The clinicopathological variables of 123 patients with PDAC registered at the National Cancer Institute in Misurata, Libya, between 2010 and 2018 were retrospectively analyzed. Blood samples from these patients were analyzed for serum CEA and CA19-9 levels before treatment by electrochemiluminescence immunoassay (double antibody sandwich ELISA) on a Roche cobas e 602 modules. The relationships between CA19-9 and CEA serum levels with clinicopathologic variables and survival outcomes were analyzed using the Kaplan-Meier method, log-rank test and Cox regression analyzes. Cut-off values for serum CEA and CA19-9 levels were 5 ng/ml and 400 U/ml, respectively. The median serum levels of all patients with PDAC for CEA and CA19-9 were 8 ng/ml (1.1-377 ng/ml) and 389 U/ml (1-10,050 U/ml), respectively. Tumors with higher serum CEA and CA19-9 levels were found in 63 and 48% of patients, respectively. Higher CEA and CA19-9 serum levels were significantly associated with more indicators of a malignant phenotype, including a surgically unresectable tumor, unevaluable lymph nodes, advanced stages and distant metastases. Regarding survival, patients with higher serum levels of the biomarkers CEA and CA19-9 had shorter overall survival rates (P<0.016 and (P<0.014, log-rank, respectively) and lower disease-free survival rates (P<0.002 and P<0.0001, log-rank, respectively)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.